ARTICLE | Clinical News
TNX-102 SL: Ph III HONOR started
April 20, 2017 9:48 PM UTC
Tonix began the double-blind, placebo-controlled, U.S. Phase III HONOR trial to evaluate 5.6 mg sublingual TNX-102 daily at bedtime for 12 weeks in about 550 patients. An IDMC will perform an interim ...
BCIQ Company Profiles